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EXTENDED REPORT
Endothelin-1 promotes vascular smooth muscle 
cell migration across the artery wall: a mechanism 
contributing to vascular remodelling and intimal 
hyperplasia in giant-cell arteritis
Ester Planas-Rigol,1 Nekane Terrades-Garcia,1 Marc Corbera-Bellalta,1 Ester Lozano,1 
Marco A Alba,1 Marta Segarra,1 Georgina Espígol-Frigolé,1 Sergio Prieto-González,1 
José Hernández-Rodríguez,1 Sara Preciado,2 Rodolfo Lavilla,2 Maria C Cid1
ABSTRACT
Background Giant-cell arteritis (GCA) is an 
inflammatory disease of large/medium-sized arteries, 
frequently involving the temporal arteries (TA). 
Inflammation-induced vascular remodelling leads to 
vaso-occlusive events. Circulating endothelin-1 (ET-
1) is increased in patients with GCA with ischaemic 
complications suggesting a role for ET-1 in vascular 
occlusion beyond its vasoactive function.
Objective To investigate whether ET-1 induces a 
migratory myofibroblastic phenotype in human TA-
derived vascular smooth muscle cells (VSMC) leading to 
intimal hyperplasia and vascular occlusion in GCA.
Methods and results Immunofluorescence/confocal 
microscopy showed increased ET-1 expression in GCA 
lesions compared with control arteries. In inflamed 
arteries, ET-1 was predominantly expressed by infiltrating 
mononuclear cells whereas ET receptors, particularly ET-1 
receptor B (ETBR), were expressed by both mononuclear 
cells and VSMC. ET-1 increased TA-derived VSMC 
migration in vitro and α-smooth muscle actin (αSMA) 
expression and migration from the media to the intima 
in cultured TA explants. ET-1 promoted VSMC motility 
by increasing activation of focal adhesion kinase (FAK), 
a crucial molecule in the turnover of focal adhesions 
during cell migration. FAK activation resulted in Y397 
autophosphorylation creating binding sites for Src 
kinases and the p85 subunit of PI3kinases which, 
upon ET-1 exposure, colocalised with FAK at the focal 
adhesions of migrating VSMC. Accordingly, FAK or PI3K 
inhibition abrogated ET-1-induced migration in vitro. 
Consistently, ET-1 receptor A and ETBR antagonists 
reduced αSMA expression and delayed VSMC outgrowth 
from cultured GCA-involved artery explants.
Conclusions ET-1 is upregulated in GCA lesions and, 
by promoting VSMC migration towards the intimal layer, 
may contribute to intimal hyperplasia and vascular 
occlusion in GCA.
INTRODUCTION
Giant-cell arteritis (GCA) is a granulomatous vascu-
litis targeting large and medium-sized arteries in 
aged individuals.1 2 Inflammation-induced vascular 
remodelling results in intimal hyperplasia leading 
to symptoms of vascular insufficiency or irreversible 
ischaemic complications in 20%–30% of patients.3–6 
It is generally assumed that vascular smooth muscle 
cells (VSMC) migrate through disrupted elastic fibres 
towards the intima where they produce abundant 
matrix proteins.6 However, underlying mechanisms 
remain virtually unexplored. Several growth factors, 
including PDGF, TGFβ, EGF, NGF or BDNF, are 
expressed in GCA lesions and may participate in this 
process based on their ability to stimulate prolifera-
tion and/or migration of VSMC in vitro.7 8
Visual loss, the most frequent ischaemic compli-
cation in GCA, is frequently preceded by transient 
episodes of blindness (amaurosis fugax) suggesting 
that reversible vasospasm may initially contribute to 
flow reduction in small arteries supplying the optic 
nerve.3–5 Endothelin-1 (ET-1) is a potent vasoactive 
peptide that might potentially participate in this 
process.9 10 ET-1 is mainly synthesised by endothe-
lial cells although VSMC and macrophages may also 
produce it.9 11 ET-1 signals through two G-protein 
coupled receptors (GPCR): E-1 receptors A and B 
(ETAR and ETBR). Both ETAR and ETBR mediate 
VSMC contraction. Signalling through ETBR on 
endothelial cells may also produce vasodilatation 
by stimulating nitric oxide and prostacyclin produc-
tion.9 10 12
Although the majority of previous studies on ET-1 
functions have focused on VSMC regulation of the 
vascular tone, in recent years, skin, liver and lung 
fibroblasts have been identified as important targets 
of ET-1.13 14 ET-1 promotes myofibroblast differenti-
ation of fibroblasts, a crucial step in the development 
of fibrogenic diseases such as systemic sclerosis and 
cardiac, pulmonary or hepatic fibrosis.13–15
The inflammatory milieu of GCA is enriched in 
cytokines and growth factors able to enhance ET-1 
expression such as TGFβ among others.9 16 We 
and others have recently shown that ET-1, ETAR 
and ETBR are increased in GCA lesions, although 
the specific cells expressing the ET-1 system 
components have not been determined.17 18 In spite 
of the short half-life of circulating ET-1, plasma 
ET-1 concentrations are elevated in patients with 
GCA-related cranial ischaemic complications.18
Since arteries involved by GCA are usually larger 
than resistance arteries controlling vascular tone, we 
hypothesised that, in addition to its vasoactive func-
tion, ET-1 might contribute to the development of 
intimal hyperplasia by stimulating a myofibroblast 
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phenotype in VSMC and promoting their migration towards the 
intimal layer. Consequently, we investigated the effect of ET-1 
on human temporal artery (TA)-derived VSMC migration in 
vitro and ex vivo as well as the signalling pathways involved.
METHODS
Patient samples
TA biopsies were performed to 10 patients with suspected GCA 
(see online supplementary table S1). Five biopsies disclosed 
typical GCA histopathological features and were used in the 
indicated experiments. The remaining five showed no inflamma-
tory lesions and served as controls. Patients with negative biop-
sies were eventually diagnosed with other conditions (see online 
supplementary table S2). The study was approved by the local 
Ethics Committee (Hospital Clinic of Barcelona) and patients 
signed informed consent.
Isolation and culture of VSMC derived from human TA
Human TA-derived VSMCs were obtained from explanted TA 
sections from the above patients cultured on Matrigel and char-
acterised by flow cytometry, as described.7 18 19 In specific exper-
iments, VSMCs were cocultured with peripheral blood mononu-
clear cells (PBMC) or purified subsets (CD4+ T cells or CD14+ 
monocytes) (online supplementary methods).
Reagents
See online supplementary methods.
Immunofluorescence
Immunofluorescence staining was performed in cultured VSMC 
or in fresh-frozen or cultured TA sections. Antibodies used, dilu-
tions and detailed steps are depicted in online supplementary 
methods.
Quantitative real-time reverse transcription PCR
RNA was extracted from cultured VSMC using TRIzol Reagent 
(Life Technologies, Paisley, UK). Prepro-ET-1 and α-smooth 
muscle actin (αSMA) mRNAs (1 µg) were measured by quan-
titative reverse transcription PCR with specific TaqMan gene 
expression assays from Applied Biosystems as reported.18
ET-1 immunoassay
ET-1 in cell supernatants was measured using R&D Quantikine 
ELISA Kit.
Migration assay
VSMC migration was assessed using Boyden chambers with 
10 µm pore polyester filters. Further details are exposed in the 
online supplementary methods.
Scratch wound-healing assay
VSMCs were seeded at 80% confluence onto 0.1% gelatin-pre-
coated 12-well plates and cultured overnight. One scratch per 
well was done before adding fresh Dulbecco's modified Eagle 
medium supplemented with 50 mmol/L of HEPES (Sigma-Al-
drich) and BQ123, BQ788 (20 µmol/L) or combination of both 
inhibitors. ET-1 (10−9 mol/L) or fresh medium was added to each 
corresponding well. Time-lapse video microscopy was applied to 
record cell movement and results were analysed as depicted in 
online supplementary methods. A proliferation assay was also 
performed to assess the potential impact of ET-1 on cell growth 
(see online supplementary figure S1).
Western blot and gelatin zymography
See details in online supplementary methods.20 21
Transient transfection
Focal adhesion kinase (FAK) wild-type cDNA and FAK point 
mutants Y397F and Y925F, cloned into the pCDNA3 expres-
sion vector, were kindly provided by Kazue Matsumoto and 
Kenneth M Yamada (National Institute of Dental and Cranio-
facial Research, National Institutes of Health, Bethesda, 
Maryland) and generated as previously described.20 22 Lipo-
fectamine 2000 Reagent (Invitrogen) was used for transient 
transfection of VSMC. Transfection efficiency was about 30% 
(see online supplementary figure S2).
Ex vivo-cultured TA sections from patients with GCA
TA sections from four treatment-naive patients with GCA and 
four controls were cultured on Matrigel as described,19 23 with or 
without BQ123 or BQ788 (20 µmol/L). VSMC outgrowth was 
scored in three arteries at various time points by two investiga-
tors (EPR and MCB) blinded to the conditions tested.7
Statistical analysis
Mann-Whitney U test for independent variables was applied 
using SPSS software, PASW V.22.0.
RESULTS
Distribution of the ET-1 system in GCA lesions compared with 
controls
In control arteries, slight ET-1 expression was observed in organised 
VSMC in the media and in the luminal endothelium (figure 1A). 
In GCA-involved arteries, ET-1 was intensively expressed by clus-
ters of infiltrating inflammatory cells (figure 1B, b.1 and figure 1C, 
c.1) and by scattered remaining VSMC (figure 1B, b.2). In addi-
tion, ET-1 expression by the luminal endothelium was increased 
(figure 1B,C) compared with control arteries (figure 1A).
To further characterise the cell types responsible for ET-1 produc-
tion in GCA, primary cultures of VSMC were obtained from normal 
TA and cocultured with purified CD4+ T lymphocytes or mono-
cytes (CD14+) from healthy donors in order to mimic vascular 
inflammation.24 Interestingly, a slight but consistent increase in 
prepro-ET-1 mRNA expression was observed in CD4+ T lympho-
cytes and to a lesser extent in CD14+ monocytes, when cocul-
tured with VSMC (figure 1D). VSMC remarkably expressed and 
secreted mature ET-1 (figure 1E). When in coculture, unprocessed 
big ET-1 increased in PBMC and decreased in VSMC lysates. 
Overall, secreted ET-1, mainly produced by VSMC, decreased in 
coculture supernatants (figure 1F). The increase in prepro-ET-1 
mRNA in PBMC cocultured with VSMC was confirmed in three 
paired experiments performed with PBMC and VSMC from the 
same GCA donor (figure 1G).
Expression of ETAR and ETBR was explored in the same TA 
specimens. In control arteries, ETAR was expressed by VSMC 
in the media whereas ETBR was hardly detected (figure 1H,I). 
In GCA, both ETAR and ETBR receptors were expressed by 
αSMA-positive cells at the intima-media border (figure 1J,K). 
Endothelial cells and inflammatory cells also expressed both ET 
receptors (figure 1J,K).
ET-1 promotes VSMC cytoskeleton reorganisation and 
migration through ETAR and ETBR
To investigate whether ET-1 promoted a myofibroblast pheno-
type in VSMC, we explored changes in cytoskeleton organisation 
induced by ET-1 in cultured TA-derived VSMC. ET-1 elicited 
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Figure 1 ET-1, ETAR and ETBR expression in GCA lesions compared with control TA. (A) Immunostaining of ET-1 (red), αSMA (green) and nuclei 
(blue) in a control TA. (B) Immunostaining of ET-1 (red), αSMA (green) and nuclei (blue) in a TA with typical GCA involvement. White arrow highlights 
ET-1 expression by the endothelium. (b.1 and b.2) Magnifications of 1B showing independent expression or coexpression of αSMA and ET-1, 
respectively. (C) Immunostaining of ET-1 (red), CD45 (green) and nuclei (blue) in a GCA-involved TA. (c.1) Magnification of 1C showing CD45+ cells 
expressing ET-1. ET-1 distribution was confirmed in three different GCA and control arteries. L, lumen; I, intima; M, media; Adv, adventitia. (D) Prepro-
ET-1 mRNA expression by purified CD4+ T cells or CD14+ monocytes isolated or cocultured with VSMC for 24 hours. Bars represent mean and SEM 
of triplicates. *p<0.05 cocultured versus isolated. (E) Immunoassay of supernatants from isolated CD4+ T lymphocytes, CD14+ monocytes or VSMC, 
or supernatants from cocultures of CD4+ T cells or CD14+ monocytes with VSMC for 24 hours. Bars represent mean and SEM of triplicates. *p<0.05 
cocultured versus isolated. (F) Big-ET-1 detection by western blot in lysates (20 µg/lane) of isolated PBMC or PBMC cocultured with VSMC, and in 
lysates of VSMC isolated or cocultured with PBMC for 24 hours. (G) Prepro-ET-1 mRNA expression by PBMC from three patients with GCA and their 
corresponding VSMC isolated or in coculture for 24 hours. (H, I) Immunofluorescence staining of ETAR (red) or ETBR (red) together with αSMA (green) 
and nuclei (blue) in a control TA and their corresponding magnifications (h.1, i.1). (J, K) Immunofluorescence staining of ETAR (red) or ETBR (red) 
together with αSMA (green) and nuclei (blue) in a GCA-involved TA and their corresponding magnifications of the endothelium (j.1, k.1), neointima 
(j.2, k.2) and media (j.3, k.3). αSMA, α-smooth muscle actin; ET-1, endothelin-1; ETAR, ET-1 receptor A; ETBR, ET-1 receptor B; GCA, giant-cell arteritis; 
RU, relative units; PBMC, peripheral blood mononuclear cells; TA, temporal arteries; VSMC, vascular smooth muscle cells.
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spreading of VSMC with a striking formation of cytoplasm 
protrusions (figure 2A). Cell spreading was not induced in VSMC 
cultured on polylysine and was more remarkable when VSMCs 
were cultured on fibronectin (figure 2A), suggesting participa-
tion of integrin-mediated signalling pathways in this process.25 
Spreading was reverted by blocking ET-1 signalling with ETAR 
antagonist BQ123 and ETBR antagonist BQ788 (figure 2A).
ET-1-induced VSMC morphology changes were associated 
with increased migratory activity (see online supplementary 
movie). ET-1 exposure resulted in significantly faster scratch-
wound closure (figure 2B). ETAR and ETBR antagonists (BQ123 
and BQ788, respectively) and combination of both inhibitors 
significantly abrogated ET-1-induced VSMC migration, indi-
cating implication of both receptors in this process (figure 2B). 
ET-1 did not accelerate scratch-wound closure by stimulating 
VSMC growth, since no significant increase in VSMC prolif-
eration was elicited by ET-1 (online supplementary figure S1).
ET-1 induced VSMC migration in Boyden chambers when 
added to the upper compartment (figure 2C). In contrast, when 
ET-1 was added to the lower compartment, no differences in 
migration were observed, indicating that ET-1 has no chemo-
attractant activity and primarily stimulates motility (figure 2C). 
ET-1-induced migration was abrogated by BQ788 and BQ123 or 
the combination of both (figure 2D).
Figure 2 Effect of ET-1 on TA-derived VSMC cytoskeleton reorganisation and migration. (A) Immunofluorescence of VSMC f-actin with phalloidin-
rhodamine (red) and nuclei (blue). VSMCs were preincubated with ETAR antagonist BQ123 (20 µmol/L), ETBR antagonist BQ788 (20 µmol/L) or both 
in suspension for 45 min. ET-1 (10−9 mol/L) was added at the time of VSMC seeding on plastic, fibronectin (5 µg/cm2) or polylysine (10 µg/mL) and 
VSMCs were incubated for 3 hours before fixing and staining. (B) Scratch wound healing assay of VSMC untreated or exposed to ET-1 (10−9 mol/L), 
with or without the presence of BQ123 (20 µmol/L), BQ788 (20 µmol/L) or both. Graph represents percentage of scratch closure over time in three 
independent experiments. (C) Boyden chamber migration assay. ET-1 was added either to the lower or in the upper compartment at the indicated 
concentrations. Cells were counted at 4× magnification. **p<0.005 for untreated cells versus ET-1-treated cells. Bars represent number of cells (mean 
and SEM of quadruplicates). (D) Boyden chamber migration assay where ET-1 was added to the upper compartment with or without preincubation 
with antagonists BQ123, BQ788 or both. Cells were counted at 10× magnification. Bars represent number of cells (mean and SEM of quadruplicates). 
(B, D) *p<0.05/**p<0.005 for untreated cells versus ET-1-treated cells. #p<0.05/##p<0.005 comparing ET-1-treated cells versus cells incubated with 
ET-1 receptor antagonists BQ123 or BQ788. ET-1, endothelin-1; ETAR, ET-1 receptor A; ETBR, ET-1 receptor B; TA, temporal arteries; VSMC, vascular 
smooth muscle cells.
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FAK phosphorylation at Y397 is essential for ET-1 induction of 
VSMC migration
Based on the relevance of integrin engagement in ET-1-induced 
cytoskeleton reorganisation, and the seminal role of FAK in inte-
grin-mediated cell motility, we explored the involvement of FAK 
in ET-induced VSMC migration. FAK is a docking and signalling 
tyrosine kinase with a seminal role in focal adhesion turnover 
required for cell migration in response to integrin binding or 
growth factor signalling.25–27
FAK activation results in autophosphorylation of crucial tyro-
sine residues.25–27 One of the best characterised is Y397 which 
provides a binding site for Src-type tyrosine kinases promoting 
their recruitment to focal adhesions and allowing their phos-
phorylation. This interaction is essential for cell migration in 
fibroblasts and malignant cells.26–29 Src, in turn, phosphorylates 
additional tyrosine residues, including Y925, located within 
the focal adhesion targeting sequence at the FAK C-terminal 
domain.30 Phosphorylated Y925 may recruit the adaptor protein 
Grb2, leading to activation of the GTP-binding protein Ras, and 
to ERK1/2 activation.30
ET-1 increased phosphorylation of Y397 and Y925 FAK 
residues (figure 3A), particularly when cells were cultured on 
plastic or fibronectin whereas this effect was absent in cells 
plated on polylysine (figure 3A,B). FAK phosphorylation was 
reduced by ETAR or ETBR antagonists BQ123 and BQ788 
(figure 3A). As G-coupled receptors, ET-1 receptors may acti-
vate heterotrimeric G proteins which have important roles 
in integrin inside-out and outside-in signalling.31 Pertussis 
toxin induces ADP-ribosylation of several Gαi subunits inhib-
iting their activity.32 As shown in figure 3C, ET-1-induced 
Y397 FAK phosphorylation was abrogated by pertussis toxin 
confirming the participation of heterotrimeric G proteins in 
ET-1-induced FAK activation.
To confirm the role of FAK in ET-1-induced VSMC migration, 
we investigated the effect of PF-573228, an inhibitor of FAK 
kinase activity. At concentrations able to inhibit FAK phosphor-
ylation (see online supplementary figure S3), PF-573228 signifi-
cantly decreased ET-1-induced VSMC cytoskeleton organisation 
and migration in a dose-dependent manner (figure 3D,E). Inter-
estingly, at low concentrations, PF-573228 inhibited ET-1-in-
duced migration whereas at higher concentrations it was also 
able to reduce baseline VSMC migration.
Consistent with a seminal role of FAK in mediating ET-1-induced 
migration, transient transfection of VSMC with FAK wild type 
significantly increased VSMC migration through Boyden chambers 
overcoming the effect of ET-1 which was not able to increase migra-
tion in FAK-overexpressing cells. However, transient transfection 
with an expression vector containing FAK Y397F point mutation 
abrogated ET-1-induced motility. In spite that ET-1 also increased 
Y925 phosphorylation, transfection of Y925F point mutant had 
no impact on ET-1-induced migration (figure 3F). These results 
indicate the crucial participation of FAK Y397 in ET-1-mediated 
migration in primary TA-derived VSMC.
It has been previously reported that integrin engagement and 
FAK signalling trigger rapid secretion of gelatinases MMP9 and 
MMP2 by lymphoid cells.20 33 Based on the important role of ET-1 
in inducing FAK activation, we explored whether ET-1 modulated 
secretion of gelatinases by VSMC. ET-1 slightly increased secretion 
of pro-MMP2 (figure 3G) and this effect was reduced by BQ788 
(ETBR antagonist) (figure 3H).
ET-1 induced FAK phosphorylation and recruitment of phos-
phorylated FAK at the focal adhesions in the leading and rear 
edges and colocalisation with αSMA (figure 4A,B).
To confirm the relevance of the above results in GCA, 
cultured TA sections from patients with GCA were assessed for 
FAK phosphorylation. As shown in figure 4C,D, Y397-phos-
phorylated FAK was detected in GCA lesions, particularly at 
the intima and intima/media junction and FAK phosphoryla-
tion decreased upon exposure to ETAR and ETBR antagonists.
Src and PI3kinases mediate ET-1-induced VSMC migration
Considering the relevance of FAK Y397 in ET-1-induced 
VSMC migration, we next explored FAK downstream pathways 
involved in cell migration including ERK, Src and PI3K.26–30 
ET-1 promoted Src activation revealed by increased phosphor-
ylation of the Y416 Src residue and this was inhibited by both 
ETAR and ETBR antagonists (figure 5A).
ERK1/2 activation has a crucial role in cell motility, by 
phosphorylating myosin light chains and as scaffolding mole-
cule.26 27 34 Although transfection with Y925F point mutant 
did not substantially reduce ET-1-induced migration, ET-1 
increased ERK1/2 phosphorylation and this was reduced by 
ET-1 receptor antagonists (figure 5A), consistent with the exis-
tence of alternative ERK activating mechanisms dependent 
and independent of FAK.26 30 Although the effect of ET-1 on 
baseline-activated Src and ERK phosphorylation was modest, 
it was consistently observed.
In accordance with the crucial role of Src in cell migration, Src 
inhibitor PP2 reduced baseline and ET-1-induced VSMC migra-
tion. Interestingly, PI3kinase inhibition with LY294002 selectively 
reduced ET-1-increased migration (figure 5B). ERK inhibition 
of ET-1-induced migration could not be assessed with PD98059 
due to the decreased viability observed after the 6-hour exposure 
required for migration experiments (see online supplementary 
figure S4). Short-term exposure to Src and ERK inhibitors, not 
reducing cell viability, virtually impeded cell spreading (figure 5C) 
whereas PI3kinase inhibition only reduced the increase in cell 
protrusions induced by ET-1 (figure 5C,D).
FAK Y397 interaction with p85, the regulatory subunit of PI3ki-
nase, is crucial to cell migration in other experimental contexts.35 36 
ET-1 promoted colocalisation of PI3kinase p85 with FAK at VSMC 
focal adhesions (figure 5D). This interaction was abrogated by 
both ETAR and ETBR antagonists and by inhibition of FAK kinase 
activity. Inhibition of PI3kinase by LY294002 prevented formation 
of fully developed cell protrusions induced by ET-1, but did not 
prevent ET-1-induced recruitment of p85 and FAK at the focal 
contacts in nascent, immature buds (figure 5D).
ET-1 induces neointima formation in ex vivo-cultured 
normal TA
In control arteries, αSMA-expressing quiescent VSMCs were 
concentrically organised (figure 6A). In contrast, in GCA-involved 
arteries the muscular layer was disrupted and αSMA-expressing 
VSMCs were mostly located at the neointima (figure 6A). Treat-
ment of cultured TA explants with ET-1 at concentrations similar 
to those found in patient plasma18 or in the coculture superna-
tants increased αSMA expression (figure 6B,C). Exposure of 
cultured normal TA to ET-1 also resulted in a striking disruption 
of the muscular layer and migration of VSMC towards the intima 
(figure 6B).
ETAR and ETBR antagonists reduce αSMA expression and 
VSMC outgrowth from ex vivo-cultured arteries from patients 
with GCA
ET-receptor antagonists BQ123 and BQ788 dramatically reduced 
αSMA expression in cultured artery sections for a patient with 
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Figure 3 Y397 FAK phosphorylation is essential for ET-1-induced TA-derived VSMC migration. (A) Immunoblot and corresponding quantification of 
total FAK or FAK phosphorylated at the indicated tyrosine residues in lysates of VSMC cultured for 90 min in the presence or the absence of ET-1 with 
or without pretreatment with ET-1 receptor antagonist BQ123 or BQ788 at the same concentrations as in previous experiments. (B) Immunoblot and 
corresponding quantification of p-FAK and total FAK in cell lysates of VSMC seeded on fibronectin (5 µg/cm2) or polylysine (10 µg/mL) and cultured for 
90 min in the presence of absence of ET-1 (10−9 mol/L). (C) Immunoblot and corresponding quantification of tyrosine 397 and total FAK from lysates 
of VSMC cultured for 90 min with or without ET-1 and with or without previous incubation with PT (1 µg/mL). (D) Immunofluorescence of VSMC 
f-actin cytoskeleton with phalloidin-rhodamine (red) and nuclei (blue). ET-1 (10−9 mol/L) was added at the time of VSMC seeding. When indicated, 
VSMCs were preincubated with a FAK inhibitor (PF-573228) at 20 µmol/L for 30 min before ET-1 exposure. Representative pictures are displayed. (E) 
Boyden chamber migration assay of VSMC preincubated with increasing concentrations of FAK inhibitor (PF-573228) with or without subsequent 
addition of ET-1. **p<0.005 untreated cells versus ET-1-treated cells. ##p<0.005 comparing ET-1-treated cells versus ET-1-treated cells preincubated 
with PF-573228. Cells were counted at 10× magnification. (F) Boyden chamber migration assay of VSMC, 3 days after transfection with empty 
pcDNA3 vector (MOCK), wild-type FAK (FAK) or FAK mutated at the phosphorylation site Y397F or Y925F. Bars represent the number of migrating 
cells (mean and SEM) of quadruplicates at 10× magnification. *p<0.05/**p<0.005 untreated cells versus ET-1-treated cells or FAK-transfected cells. 
#p<0.05/##p<0.005 for the indicated comparisons. Notice that baseline migration in transfected cells is globally inferior than in non-manipulated 
cells displayed in figure 2. (G) Gelatin zymography of serum-free supernatants of VSMC cultured in the absence or in the presence of ET-1 for 6 hours. 
A representative experiment out of three is displayed. (H) Gelatin zymography of serum-free supernatants of VSMC cultured in the presence or in 
the absence of ET-1 (10−9 mol/L) and ET-1 receptor antagonists BQ123 and BQ788 (20 µmol/L) for 6 hours. A representative experiment out of two is 
displayed. ET-1, endothelin-1; FAK, focal adhesion kinase; MMP2, matrix metalloproteinase 2; PT, pertussis toxin; TA, temporal arteries; VSMC, vascular 
smooth muscle cells.
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GCA (figure 6D). Blocking ETBR with BQ788 remarkably inhib-
ited VSMC outgrowth from GCA-involved arteries (figure 6E). 
The effect of blocking ETAR with BQ123 was less intense but also 
delayed VSMC outgrowth (figure 6E). Taking together, these data 
support a seminal role of ET-1 in inducing neointima formation in 
GCA.
DISCUSSION
Expression of ET-1 was increased in GCA lesions compared with 
normal arteries. In GCA, infiltrating leukocytes accounted for 
the majority of ET-1 expression, which was also enhanced in the 
luminal endothelium. Some ET-1 expression was also observed in 
remaining VSMC. Coculture experiments supported that, in an 
Figure 4 FAK recruitment and phosphorylation at the cell protrusions of ET-1-stimulated VSMC and in ex vivo-cultured TA from patients with 
GCA. (A) Tracked migratory VSMC exposed to ET-1 (see online supplementary movie). Direction of the migration is indicated by the arrow. (B) 
Immunofluorescence of total FAK (red) or phospho-Y397 FAK (green), nuclei (blue) and actin cytoskeleton (red) of VSMC cultured in the presence or 
in the absence of ET-1 (10−9 mol/L) as labelled. Arrows indicate FAK colocalisation with αSMA at the focal adhesions in cell protrusions of migrating 
cells. (C) Immunofluorescence of pY397 FAK (green), total FAK (red) and nuclei (blue) of a TA from a patient with GCA cultured on Matrigel for 5 
days untreated or treated with ETAR or ETBR antagonist (BQ123 and BQ788, respectively) at 20 µmol/L. L, lumen; I, intima layer; M, media layer; Adv, 
adventitia. (D) Magnified VSMC from the media-intima junction of an untreated TA shown in C. Arrow indicates coexpression of phospho-Y397 FAK 
and total FAK at the media-intima junction of the untreated GCA artery. Separated channels and merge are displayed. Representative picture of 
multiple cells coexpressing Y397 FAK with FAK. αSMA, α-smooth muscle actin; ET-1, endothelin-1; ETAR, ET-1 receptor A; ETBR, ET-1 receptor B; FAK, 
focal adhesion kinase; GCA, giant-cell arteritis; TA, temporal arteries; VSMC, vascular smooth muscle cells.
group.bmj.com on March 22, 2018 - Published by http://ard.bmj.com/Downloaded from 
8 Planas-Rigol E, et al. Ann Rheum Dis 2017;0:1–11. doi:10.1136/annrheumdis-2016-210792
Basic and translational research
inflammatory microenvironment, ET-1 production is increased 
in mononuclear cells and decreases in VSMC. ETAR was consti-
tutively expressed by VSMC in normal arteries but, in the context 
of vascular inflammation, both ET receptors were remarkably 
increased and expressed by endothelial cells, VSMC and infil-
trating leukocytes. As previously reported, the increase in ETBR 
was much more prominent.17
ET-1 stimulated VSMC migration through FAK activation, 
revealed by ET-1-enhanced FAK autophosphorylation at Y397, 
creating binding sites for Src kinase and the p85 regulatory 
subunit of PI3kinase, a crucial process in cell motility.29 30 35 ET-1 
promoted colocalisation of activated FAK and p85-PI3kinase at the 
focal adhesions. Subsequent signalling cascades participating in cell 
motility in other cell types, such as Src and ERK, were also slightly 
activated. Interestingly, while FAK and Src inhibitors strongly 
reduced both baseline and ET-1-induced migration, PI3kinase 
inhibitor selectively inhibited the increase in migration induced 
by ET-1. Class I PI3kinases are activated by tyrosine kinases 
whereas class II PI3kinases are activated through GPCR.36 37 It is 
likely that ET-1 promotes activation of both classes of PI3kinases 
through FAK activation and through GPCR ETAR and ETBR. In 
addition, GPCR-induced heterotrimeric G-protein activation may 
Figure 5 ERK, Src and PI3K participation in ET-1 induced VSMC migration. (A) Immunoblot of phospho-Src (Y416)/total Src and phospho ERK/total 
ERK in lysates of VSMC treated with ET-1 (10−9 mol/L) for 90 min. Graphs show quantification of a representative experiment out of three independent 
experiments. (B) VSMC migration in Boyden chambers with or without preincubation with Src inhibitor PP2 (10 μmol/L), or PI3K inhibitor LY294002 
(20 µmol/L), with or without subsequent addition of ET-1. Bars represent the number of migrated cells (mean and SEM of quadruplicates). **p<0.005 
for untreated cells versus ET-1-incubated cells. ##p<0.005 for ET-1-treated cells versus VSMC preincubated with inhibitors. (C) Immunofluorescence 
of VSMC f-actin cytoskeleton (red) and nuclei (blue). ET-1 was added at the time of VSMC seeding. VSMCs were preincubated 30 min in suspension 
with Src inhibitor (PP2), ERK inhibitor (PD98059) or PI3K inhibitor (LY294002) before addition of ET-1 (10−9 mol/L). Representative pictures of each 
situation are shown. (D) Immunofluorescence staining of f-actin cytoskeleton (blue), p85 (green), total FAK (red) and nuclei (white) in VSMC treated 
with ET-1, or ET-1 plus ETAR antagonist (BQ123), ETBR antagonist (BQ788), PI3K inhibitor (LY294002) or FAK inhibitor (PF-573228) as labelled. Arrows 
highlight p85 and FAK colocalisation in the cell protrusions of ET-1-treated VSMC or p85/FAK clusters in immature cell protrusions triggered by ET-1 
in the presence of PI3kinase inhibitor LY294002. ET-1, endothelin-1; ETAR, ET-1 receptor A; ETBR, ET-1 receptor B; FAK, focal adhesion kinase; VSMC, 
vascular smooth muscle cells.
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also contribute to FAK activation since pertussis toxin abrogated 
ET-1-induced FAK phosphorylation.
It has been previously shown that FAK coordinates migra-
tion with matrix metalloproteinase (MMP) release, which 
is necessary for cell progression through the extracellular 
matrix.20 ET-1 moderately stimulated release of MMP2 by 
VSMC, a process mostly mediated by ETBR in our exper-
imental conditions. Since MMP2 has elastinolytic activity, 
ET-1-induced MMP-2 release may be relevant to the disrup-
tion of the internal elastic lamina, characteristically observed 
Figure 6 ET-1 induction of VSMC migration in ex vivo TA cultures. (A) Immunofluorescence staining of αSMA (red) and nuclei (blue) in a control 
TA (left panel) or in a GCA artery with typical lesions (right panel). (B) Immunofluorescence staining of αSMA (red) and nuclei (blue) in a control TA 
cultured on Matrigel for 5 days in the presence or in the absence of ET-1 (10−9 mol/L). Arrows indicate αSMA-positive cells migrating from the media 
to the intimal layer. Pictures are representative of three different control arteries. L, lumen; I, intimal layer; M, media layer. (C) αSMA mRNA expression 
in three cultured normal arteries in the absence or in the presence of ET-1 (10−9 mol/L) (upper panel). Immunoblot of αSMA and β-actin, with the 
corresponding quantifications, in a normal TA cultured for 5 days in the absence or in the presence of ET-1 at the same concentration. The experiment 
was repeated twice with consistent results. (D) Immunofluorescence staining of αSMA (red) and nuclei (blue) in a control TA cultured in Matrigel for 5 
days (left panel) and in a GCA-involved artery (right panel) in the presence or absence of ET-1 receptor antagonists (BQ123 and BQ788) at 20 µmol/L. 
(E) VSMC outgrowth from three TAs from patients with GCA cultured on Matrigel for the indicated periods of time with or without the presence of 
ET-1 receptor antagonist BQ123 (20 µmol/L) or BQ788 (20 µmol/L). αSMA, α-smooth muscle actin; ET-1, endothelin-1; GCA, giant-cell arteritis; RU, 
relative units; TA, temporal arteries; VSMC, vascular smooth muscle cells.
group.bmj.com on March 22, 2018 - Published by http://ard.bmj.com/Downloaded from 
10 Planas-Rigol E, et al. Ann Rheum Dis 2017;0:1–11. doi:10.1136/annrheumdis-2016-210792
Basic and translational research
in GCA lesions, allowing VSMC migration from the muscular 
to the intimal layer.6 21 38
FAK has received substantial attention in pathological 
processes where cell migration is seminal including cancer and 
fibrosis.14 28 Our data suggest that FAK is involved in vascular 
remodelling. Supporting our findings, a recent study has 
evidenced Y397 phosphorylated FAK in the resistance arteries 
undergoing vascular remodelling in hypertension.39 Selective 
myeloid deletion of FAK does not influence vascular remodelling 
in a mouse model, suggesting that expression and activation of 
FAK in VSMC rather than inflammatory cells may be relevant to 
vascular occlusion.40 Moreover, a naturally occurring truncated 
form of FAK, FRNK, which acts as competitive inhibitor of FAK, 
inhibits VSMC invasion in a carotid rat injury model.41 Conse-
quently, our results indicate that ET-1-mediated activation of 
FAK in VSMC may have a seminal role in vascular remodelling 
in the context of vascular inflammation where ET-1 is mainly 
produced by inflammatory cells and their production is ampli-
fied through interactions with VSMC. These newly recognised 
functions of ET-1 on VSMC may have a broader impact and may 
operate in vascular diseases with prominent vascular remodel-
ling beyond GCA. To date, in the field of vascular biology, atten-
tion has mainly focused on the vasoconstriction role of ET-1 
and only responses related to vascular reactivity or hyperten-
sion have been explored after conditional deletion of ETAR in 
VSMC.9 10 41 In a pioneer study performed in mice more than 
one decade ago, induced overexpression of ET-1 in endothelial 
cells resulted in increased vascular remodelling.42 However, this 
interesting observation has not been further explored.
Based on its presumed major function, ET-1 has been consid-
ered a therapeutic target for vascular diseases where vasocon-
striction is thought to play a major role such as systemic or 
pulmonary hypertension or, more recently, fibrotic diseases, 
such as scleroderma or lung fibrosis, according to the newly 
recognised functions of ET-1 on fibroblasts.9 10 13 14 However, to 
date, clinical trials with ET-1 receptor antagonists have shown 
the best efficacy for diseases with prominent vascular remod-
elling such as ischaemic ulcers in systemic sclerosis or pulmo-
nary hypertension rather than vasoconstriction or fibrotic 
diseases.9 10 43
There is an unmet need of treatments reducing inflamma-
tion-induced vascular remodelling in GCA since patients with 
systemic vasculitis may develop complications derived from 
vascular occlusion in spite of glucocorticoid or immunosuppres-
sive therapy.44 Our data underline an unprecedented and crucial 
role for ET-1 in inducing vascular remodelling and vascular 
occlusion in the context of vascular inflammation and point 
towards endothelin receptor antagonists as potential therapeutic 
targets to avoid maladaptive vascular remodelling in inflamma-
tory diseases of blood vessels.
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